PMID- 22833405
OWN - NLM
STAT- MEDLINE
DCOM- 20130118
LR  - 20180802
IS  - 1424-3997 (Electronic)
IS  - 0036-7672 (Linking)
VI  - 142
DP  - 2012
TI  - Sustained improvement in left ventricular function after bone marrow derived cell 
      therapy in patients with acute ST elevation myocardial infarction. A 5-year 
      follow-up from the Stem Cell Transplantation in Ischaemic Myocardium Study.
PG  - w13632
LID - 10.4414/smw.2012.13632 [doi]
AB  - BACKGROUND: Intracoronary injection of autologous bone marrow-derived 
      mononucleated cells (BM-MNC) may improve LV function shortly after acute ST 
      elevation myocardial infarction (STEMI), but little is known about the long-term 
      durability of the treatment effect. METHODS: In a single-centre trial a total of 
      60 patients with acute anterior STEMI, successful reperfusion therapy and a left 
      ventricular ejection fraction (LVEF) of <50% were screened for the study. 23 
      patients were actively treated with intracoronary infusion of BM-MNC within a 
      median of 3 days. The open-label control group consisted of 19 patients who did 
      not consent to undergo BM-MNC treatment but agreed to undergo regular clinical 
      and echocardiographic follow-up for up to 5 years after AMI. RESULTS: Whereas at 
      4 months there was no significant difference between the increase in LVEF in the 
      BM-MNC group and the control group (+7.0%, 95%CI 3.6; 10.4) vs. +3.9%, 95%CI 
      -2.1; 10), the absolute increase at 5 years remained stable in the BM-MNC but not 
      in the control group (+7.95%, 95%CI 3.5; 12.4 vs. -0.5%, 95%CI -5.4; 4.4; p for 
      interaction between groups = 0.035). DISCUSSION: In this single-centre, 
      open-labelled study, intracoronary administration of BM-MNC is feasible and safe 
      in the short term. It is also associated with sustained improvement of left 
      ventricular function in patients with acute myocardial infarction, encouraging 
      phase III studies to examine the potential BM-MNC effect on clinical outcome.
FAU - Moccetti, Tiziano
AU  - Moccetti T
AD  - Fondazione Cardiocentro Ticino, Lugano, Switzerland.
FAU - Surder, Daniel
AU  - Surder D
FAU - Klersy, Catherine
AU  - Klersy C
FAU - Vassalli, Giuseppe
AU  - Vassalli G
FAU - Crljenica, Carmen
AU  - Crljenica C
FAU - Rossi, Maria Grazia
AU  - Rossi MG
FAU - Pasotti, Elena
AU  - Pasotti E
FAU - Soldati, Gianni
AU  - Soldati G
LA  - eng
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120725
PL  - Switzerland
TA  - Swiss Med Wkly
JT  - Swiss medical weekly
JID - 100970884
SB  - IM
CIN - Swiss Med Wkly. 2012;142:w13633. PMID: 22832910
MH  - Aged
MH  - *Bone Marrow Transplantation
MH  - Echocardiography
MH  - Electrocardiography
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Leukocytes, Mononuclear/*transplantation
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/physiopathology/*therapy
MH  - Treatment Outcome
MH  - *Ventricular Function, Left
EDAT- 2012/07/27 06:00
MHDA- 2013/01/19 06:00
CRDT- 2012/07/27 06:00
PHST- 2012/07/27 06:00 [entrez]
PHST- 2012/07/27 06:00 [pubmed]
PHST- 2013/01/19 06:00 [medline]
AID - smw-13632 [pii]
AID - 10.4414/smw.2012.13632 [doi]
PST - epublish
SO  - Swiss Med Wkly. 2012 Jul 25;142:w13632. doi: 10.4414/smw.2012.13632. eCollection 
      2012.